Chardan Capital Maintains Buy on Editas Medicine, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has maintained a Buy rating on Editas Medicine but lowered the price target from $20 to $12.
October 22, 2024 | 10:04 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Chardan Capital has maintained its Buy rating on Editas Medicine but has reduced the price target from $20 to $12, indicating a more cautious outlook.
The maintenance of a Buy rating suggests continued confidence in the company's prospects, but the lowered price target reflects a more cautious stance on its valuation. This mixed signal may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100